PolyPid to Participate in the 37th Annual ROTH Conference
PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has announced its participation in the 37th Annual ROTH Conference in Dana Point, California, scheduled for March 17-18, 2025.
The company will conduct a fireside chat, which will be available on-demand starting Monday, March 17, 2025, at 2:00 PM PT. Additionally, the management team will engage in one-on-one investor meetings during the event. Interested investors seeking meetings with PolyPid should coordinate through their ROTH representative.
PolyPid (Nasdaq: PYPD), un'azienda biofarmaceutica in fase avanzata focalizzata sul miglioramento dei risultati chirurgici, ha annunciato la sua partecipazione alla 37ª Conferenza Annuale ROTH a Dana Point, California, prevista per il 17-18 marzo 2025.
L'azienda condurrà una chiacchierata informale, che sarà disponibile on-demand a partire da lunedì 17 marzo 2025, alle 14:00 PT. Inoltre, il team di gestione parteciperà a incontri individuali con gli investitori durante l'evento. Gli investitori interessati a fissare incontri con PolyPid devono coordinarsi attraverso il loro rappresentante ROTH.
PolyPid (Nasdaq: PYPD), una empresa biofarmacéutica en etapa avanzada centrada en mejorar los resultados quirúrgicos, ha anunciado su participación en la 37ª Conferencia Anual ROTH en Dana Point, California, programada para el 17 y 18 de marzo de 2025.
La empresa llevará a cabo una charla informal, que estará disponible a demanda a partir del lunes 17 de marzo de 2025, a las 2:00 PM PT. Además, el equipo directivo participará en reuniones individuales con inversores durante el evento. Los inversores interesados en reunirse con PolyPid deben coordinarse a través de su representante de ROTH.
PolyPid (Nasdaq: PYPD), 외과적 결과 개선에 집중하는 후기 단계의 바이오 제약 회사가 2025년 3월 17일과 18일에 캘리포니아 다나 포인트에서 열리는 제37회 연례 ROTH 컨퍼런스에 참여한다고 발표했습니다.
회사는 2025년 3월 17일 월요일 오후 2시 PT부터 주문형으로 제공될 수 있는 파이어사이드 채팅을 진행할 예정입니다. 또한 관리 팀은 행사 기간 동안 투자자와의 일대일 미팅에 참여할 것입니다. PolyPid와의 미팅을 원하는 투자자는 ROTH 대표를 통해 조정해야 합니다.
PolyPid (Nasdaq: PYPD), une entreprise biopharmaceutique en phase avancée axée sur l'amélioration des résultats chirurgicaux, a annoncé sa participation à la 37e Conférence Annuelle ROTH à Dana Point, Californie, prévue pour les 17 et 18 mars 2025.
L'entreprise organisera une discussion informelle, qui sera disponible à la demande à partir de lundi 17 mars 2025, à 14h00 PT. De plus, l'équipe de direction participera à des réunions individuelles avec des investisseurs lors de l'événement. Les investisseurs intéressés souhaitant rencontrer PolyPid doivent se coordonner avec leur représentant ROTH.
PolyPid (Nasdaq: PYPD), ein biopharmazeutisches Unternehmen in der späten Phase, das sich auf die Verbesserung chirurgischer Ergebnisse konzentriert, hat seine Teilnahme an der 37. jährlichen ROTH-Konferenz in Dana Point, Kalifornien, bekannt gegeben, die für den 17.-18. März 2025 geplant ist.
Das Unternehmen wird ein informelles Gespräch führen, das ab Montag, den 17. März 2025, um 14:00 Uhr PT auf Abruf verfügbar sein wird. Darüber hinaus wird das Management-Team während der Veranstaltung an persönlichen Investorengesprächen teilnehmen. Interessierte Investoren, die Meetings mit PolyPid wünschen, sollten sich über ihren ROTH-Vertreter koordinieren.
- None.
- None.
PETACH TIKVA, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will present at the 37th Annual ROTH Conference taking place in Dana Point, California, from March 17-18, 2025.
PolyPid’s fireside chat will be available on-demand beginning on Monday, March 17, 2025, at 2:00 PM PT via the conference platform using the following link.
The PolyPid management team will participate in one-on-one investor meetings during this event. Investors interested in meeting with PolyPid around the conference should contact their ROTH representative.
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.
For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.
Contacts:
PolyPid Ltd.
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com
Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
britchie@lifesciadvisors.com
FAQ
When is PolyPid (PYPD) presenting at the ROTH Conference 2025?
Where is the 37th Annual ROTH Conference with PYPD being held?
How can investors meet with PolyPid management at the ROTH Conference?
What is PolyPid's (PYPD) current business focus?
